CEPHALEXIN capsule

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

CEPHALEXIN (UNII: OBN7UDS42Y) (CEPHALEXIN ANHYDROUS - UNII:5SFF1W6677)

Available from:

Central Texas Community Health Centers

INN (International Name):

CEPHALEXIN

Composition:

CEPHALEXIN ANHYDROUS 500 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae and Streptococcus pyogenes. Cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis. Cephalexin capsules are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes . Cephalexin capsules are indicated for the treatment of bone infections caused by susceptible isolates of Staphylococcus aureus and Proteus mirabilis. Cephalexin capsules are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae . To reduce the development of drug-resist

Product summary:

Cephalexin capsules, USP are available in: 250 mg Capsule Dark green opaque/white size "2" hard gelatin capsule filled with off white granular powder and imprinted with "A 42" on dark green opaque cap and "250 mg" on white body with black ink. Bottles of 20                                                               NDC 65862-018-20 Bottles of 40                                                               NDC 65862-018-40 Bottles of 100                                                             NDC 65862-018-01 Bottles of 500                                                             NDC 65862-018-05 500 mg Capsule Dark green opaque/light green opaque size "0" hard gelatin capsule filled with off white granular powder and imprinted with "A 43" on dark green opaque cap and "500 mg" on light green opaque body with black ink. Bottles of 20                                                               NDC 65862-019-20 Bottles of 40                                                               NDC 65862-019-40 Bottles of 100                                                             NDC 65862-019-01 Bottles of 500                                                             NDC 65862-019-05 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].  Dispense in a tight, light-resistant container.

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

CEPHALEXIN - CEPHALEXIN CAPSULE
CENTRAL TEXAS COMMUNITY HEALTH CENTERS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CEPHALEXIN CAPSULESSAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CEPHALEXIN CAPSULES
CEPHALEXIN CAPSULES, FOR ORAL USE
INITIAL U.S. APPROVAL: 1971
INDICATIONS AND USAGE
Cephalexin capsules are a cephalosporin antibacterial drug indicated
for the treatment of the following infections caused by
susceptible isolates of designated bacteria:
Respiratory tract infection (1.1)
Otitis media (1.2)
Skin and skin structure infections (1.3)
Bone infections (1.4)
Genitourinary tract infections (1.5)
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of cephalexin capsules and other
antibacterial drugs, cephalexin capsules should be used only to treat
infections that are proven or strongly suspected to be
caused by bacteria. (1.6)
DOSAGE AND ADMINISTRATION
Adults and patients at least 15 years of age
The usual dose is 250 mg every 6 hours, but a dose of 500
mg every 12 hours may be administered (2.1)
Pediatric
patients (over 1
year of age)
Otitis media: 75 to 100 mg/kg in equally divided doses
every 6 hours (2.2)
All other indications: 25 to 50 mg/kg given in equally
divided doses (2.2)
In severe infections: 50 to 100 mg/kg may be
administered in equally divided doses (2.2)
Duration of therapy ranges from 7 to14 days depending on the infection
type and severity. (2)
Dosage adjustment is required in patients with severe and end stage
renal disease (ESRD) defined as creatinine
clearance below 30 mL/min. (2.3)
DOSAGE FORMS AND STRENGTHS
Capsules: 250 mg and 500 mg (3)
CONTRAINDICATIONS
Patients with known hypersensitivity to cephalexin or other members of
the cephalosporin class of antibacterial drugs. (4)
WARNINGS AND PRECAUTIONS
Serious hypersensitivity (anaphylactic) reactions: Prior to use,
inquire regarding history of hypersensitivity to beta-
lactam antibacterial drugs. Discontinue the drug if